Related Experiment Video
Updated: Jul 9, 2026
Use of Rabbit Eyes in Pharmacokinetic Studies of Intraocular Drugs
Published on: July 23, 2016
[Spectrofluorimetric changes in the lens after intravitreal injections of brolucizumab]
V V Gar'kavenko1, V V Salmin2,3,4, P M Balashova1,5
1Krasnoyarsk Regional Ophthalmological Clinical Hospital named after Professor P.G. Makarov, Krasnoyarsk, Russia.
Abstract:
Intravitreal injections (IVI) of vascular endothelial growth factor (VEGF) inhibitors are actively used in the treatment of various ophthalmic pathologies. In addition to the pronounced therapeutic effect of anti-VEGF drugs described in the literature, a number of data on adverse effects associated with the use of IVI, including from the lens, have now been accumulated. Prevention of possible side effects of this type of treatment requires further investigation.
Purpose:
The study evaluates the changes in spectrofluorometric parameters of the lens after intravitreal injections of brolucizumab in eyes with native lens.
Material And Methods:
The study included 13 people with neovascular age-related macular degeneration (AMD) who received IVI of brolucizumab. All patients were over 40 years old; changes in central retinal thickness in the macular area exceeded 300 μm according to optical coherence tomography. Spectrofluorimetric indicators of the lens were studied before and after injections of the drug in both eyes. The spectra were analyzed in the wavelength range 412-698 nm to record the changes in the content of non-tryptophan fluorophore molecules in the lens.
Results:
Spectrofluorimetry revealed metabolic changes in the native lens after intravitreal injections of the drug brolucizumab. No such changes were observed in the lens of the eyes not injected with the drug (the «Control» group). The proposed investigation technique involves prospective assessment of the safety of various molecules injected intravitreally in terms of cataract development at various times after the injection.
Conclusion:
Spectrofluorimetry can be used for identifying initial metabolic changes in the lens. It is a promising method for assessing the molecules used in intravitreal injections in terms of their safety for the native lens, as well as for development of detailed instructions for clinically substantiated use of drugs with adverse effects in the form of cataract induction. According to spectrofluorimetry, IVI of the drug brolucizumab affects metabolic changes in the lens.
More Related Videos
07:13An Alternative and Validated Injection Method for Accessing the Subretinal Space via a Transcleral Posterior Approach
Published on: December 7, 2016
07:12Spatio-Temporal In Vivo Imaging of Ocular Drug Delivery Systems using Fiberoptic Confocal Laser Microendoscopy
Published on: September 27, 2021
